Johnson & Johnson (NYSE:JNJ) VP Sells $11,291,841.52 in Stock

Johnson & Johnson (NYSE:JNJ) VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.31% during mid-day trading on Friday, reaching $132.63. 4,792,761 shares of the company’s stock traded hands. The company has a market cap of $355.98 billion, a P/E ratio of 22.44 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company’s 50 day moving average is $132.88 and its 200 day moving average is $127.04.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter last year, the business earned $1.74 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (NYSE:JNJ) VP Sells $11,291,841.52 in Stock” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/08/19/dominic-j-caruso-sells-82591-shares-of-johnson-johnson-nysejnj-stock-updated-updated-updated.html.

Hedge funds have recently made changes to their positions in the stock. Lau Associates LLC raised its stake in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after buying an additional 5,335 shares during the period. Loomis Sayles & Co. L P raised its stake in shares of Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock valued at $12,768,000 after buying an additional 88,510 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock valued at $1,627,000 after buying an additional 957 shares during the period. Burke & Herbert Bank & Trust Co. raised its stake in shares of Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock valued at $5,895,000 after buying an additional 1,218 shares during the period. Finally, Coho Partners Ltd. raised its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Coho Partners Ltd. now owns 529,138 shares of the company’s stock valued at $60,962,000 after buying an additional 3,201 shares during the period. Institutional investors and hedge funds own 66.10% of the company’s stock.

A number of equities research analysts have commented on the stock. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a research report on Sunday, May 14th. Royal Bank Of Canada reissued a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a research report on Friday, July 21st. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $134.12.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit